NCT05895513View on ClinicalTrials.gov

Pimavanserin and Aggression and Social Cognition.

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Intermittent Explosive Disorder
Interventions
DRUG

Pimavanserin 34 mg

5HT-2a receptor antagonist

DRUG

Placebo

Inactive Comparator

Trial Locations (1)

43210

RECRUITING

The Ohio State University College of Medicine, Columbus

Sponsors
All Listed Sponsors
collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

lead

Ohio State University

OTHER